Definium Therapeutics
A Senior Director, Payer Marketing at Definium Therapeutics develops marketing materials and strategies for payers and channel partners, translating clinical and economic evidence into compelling content that drives coverage and reimbursement for DT-120 ODT.
Headquarters
New York, New York, United States
Company Size
1-10 employees
Founded
2019
Definium Therapeutics (formerly MindMed) is a clinical-stage biopharmaceutical company harnessing the therapeutic potential of psychedelic medicine to develop treatments for psychiatric conditions including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Its lead programs include DT120 ODT, a proprietary formulation of lysergide (LSD) D-tartrate, and DT402, the R-enantiomer of MDMA targeting core symptoms of autism spectrum disorder. The company is guided by precision science and evidence-based development to redefine mental healthcare.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Definium Therapeutics.
132% above the average for this role
Director, National Payer Accounts
Compass Pathways
Senior Manager, Payer Marketing
The Bountiful Company
Director, Account Management (Northeast Region)
Axsome Therapeutics
Market Director Payer Strategy TX
California Hospital Medical Center Foundation
Payer Engagement Account Director (Market Access) #4606
GRAIL
Associate Director, Payer Marketing, Respiratory
MSD